EcoR1 Capital, LLC has made notable moves in the stock market by acquiring additional shares of AnaptysBio, Inc. This activity, detailed in a recent SEC filing, underscores EcoR1's commitment to its investment strategy in the pharmaceutical sector.

EcoR1 Capital, LLC, based in San Francisco, California, is a private investment firm that focuses on life sciences and healthcare investments. The firm has been actively involved in the market, as evidenced by its recent filings, including a Form 4 on November 18, 2026, which details its transactions involving AnaptysBio, Inc., a company engaged in pharmaceutical preparations.

What the Filing Says

The filing reveals that EcoR1 Capital, LLC, through its manager Oleg Nodelman, has executed multiple transactions involving AnaptysBio's common stock. On November 16, 2026, EcoR1 acquired 84,120 shares at a price of $45.6624 per share. This was followed by additional purchases of 152,367 shares on November 17 at $45.6553 per share, and 138,093 shares on November 18 at $46.5419 per share. Following these transactions, EcoR1's total ownership in AnaptysBio increased significantly, with 8,254,674 shares now held.

Impact

This increase in share ownership may affect various stakeholders, including EcoR1's investors and the broader market for AnaptysBio. As EcoR1 continues to build its stake, it may influence the company's strategic direction and market performance. The pharmaceutical preparations sector might also see shifts as investment dynamics change with such significant holdings.

What's Next

The filing does not specify what happens next regarding EcoR1's investment strategy or any potential future transactions.